LinkMed acquire major sales channel

LinkMed acquire major sales channel

LinkMed acquires NorDiag´s 50 percent stake in Olerup International AB,
which is the holding company for Olerup GmbH. LinkMed will thereby
control 75 percent of the company. Both sales and earnings are
consolidated into the Group as of June 1, 2011. Net sales are expected
to increase on an annual basis by approximately SEK 28 million and the
profit on EBIT level of SEK 8-10 million.

LinkMed increases its ownership in Olerup International AB to 75 percent
by acquiring NorDiag 50 percent stake in Olerup International AB which
is the holding company of Olerup GmbH. The remaining 25 percent of
Olerup International is owned by Olle Olerup. The acquisition leads to a
termination of the Joint Venture with NorDiag. NorDiag's product Arrow
will not continue to be sold by Olerup GmbH.

LinkMed will pay in cash total SEK 8 million for NorDiag's part of
Olerup International AB. The cash payment for the shares is divided into
two tranches, whereby SEK 5 million will be paid upon the transfer of
the shares and SEK 3 million will be paid no later than 31 October 2011.

Olerup GmbH is responsible for sales of Olerup SSP® and XM-ONE® in all
markets outside North- and South America with direct sale in
Scandinavia, Germany, Austria and Slovenia, while the rest of the market
is covered by some 30 sub-distributors. Olerup GmbH accounts for about
80 percent of Olerup SSP® total sales and the LinkMed subsidiary Olerup
Inc. in the U.S. accounts for the remaining 20 percent.

"The acquisition has a lot of positive implications for us in the short
and long term in our strategy to become a global transplantation
company. Sales and profit increases but equally important is that we now
can focus on growth in a better way and work more direct with the
customers. The acquisition is also very well-timed as we are now
launching the SBT products from Conexio. The SBT products are expected
within a few years to sell as much as the SSP products and we now have
the full margin in the chain that will give us a very good profit
development, "said LinkMed's CEO Ingemar Lagerlöf.

Olerup SSP
Olerup SSP® are products for PCR-based typing of HLA. The products are
used to match patients and donors in hematopoietic stem cell and organ
transplantations. Olerup SSP currently offers around 115-120 different
typing kits, covering the approximately 6,000 different HLA variants
that have been identified to date. Approximately five new HLA alleles
are identified per day. It takes one to a few months to update all the
kits for the new alleles. Olerup SSP offers both products for
high-resolution and low resolution HLA typing with very low frequency of
false positive and false negative reactions.

XM-ONE
XM-ONE® is the first standardized test for detecting antibodies against
the endothelium. These endothelial cells are the first point of contact
between the graft and the recipient's immune system. Antibodies to
endothelium have been shown to play an important role in rejection
reactions after transplantation. In a recent study presented in the
recognized journal Transplantation, a research group at Johns Hopkins
School of Medicine in Baltimore, USA have shown that patients with
antibodies to endothelial cells showed that the cross test XM-ONE® has
significantly higher risk of being involved in rejection compared with
patients who are negative in this test.

SBT products
SBT Resolver™, HLA typing by SBT technology and software for sequence
analysis from Conexio. Conexios SBT Resolver ™ is a locus-specific
PCR-based line of products for sequence based typing (SBT) of HLA. The
products are used to match patients and donors in hematopoietic stem
cell and organ transplantation. LinkMed exclusive marketing and
distribution agreement covers SBT kit and a version of software for
sequence analysis in all markets except Australia and New Zealand.

LinkMed AB discloses the information provided herein pursuant to the
Securities Markets Act and/or the Financial Instruments Trading Act. The
information was submitted for publication at 08:00 (CET) on May 24,
2011.

For more information please contact:
Ingemar Lagerlöf, CEO LinkMed tel: +46 708-73 27 33, email:
ingemar.lagerlof@linkmed.se

Or visit www.linkmed.se